retatrutide

• Triple‑pathway activation — Retatrutide uniquely targets GIP, GLP‑1, and glucagon receptors at the same time, creating a broader metabolic response than single‑pathway peptides.

• Enhanced appetite regulation — GLP‑1 and GIP activity work together to reduce hunger signals and increase satiety.

• Improved glucose handling — Supports insulin secretion and helps stabilise blood sugar through incretin‑based signalling.

• Increased energy expenditure — Glucagon receptor activation may elevate metabolic rate and promote fat oxidation.

• Comprehensive metabolic support — The combined receptor engagement delivers a multi‑layered approach to weight, glucose, and energy balance.